A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa
NCT07727889
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Hidradenitis Suppurativa (Acne Inversa)
Interventions
DRUG:
Upadacitinib
Sponsor
Peking Union Medical College